A Study of Bedaquiline-Containing Regimens for MDR and XDR-TB Treatment
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 4, Pages 1402-1406
AbstractIntroduction: Due to its protracted duration, toxicity, high expense, and unfavourable
results, the treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR)
tuberculosis (TB) has proven difficult during the past few decades.
Methods: A prospective study with 50 drug-resistant tuberculosis patients who are
taking bedaquiline as part of a treatment regimen and who meet the requirements of
being over 18 years old, all genders, and having biological samples that show drug
resistance that has been confirmed by phenotypic or genetic testing.
Results: Nausea was the most frequent side effect, followed by diarrhoea, joint
discomfort, anorexia, and itching. There was no hepatotoxic effect.
Conclusion: A regimen using bedaquiline produced positive results. The benefit clearly
justifies the risk even though bedaquiline and concurrent anti-TB medicines have the
potential to lengthen QTc interval.
- Article View: 18
- PDF Download: 33